WHO ICTRP trial
Phase II trial with Cetuximab and Irinotecan (CetIri) for patients with platinum…
EUCTR2008-006168-12-DK · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2008-006168-12-DK |
|---|---|
| Public title | Phase II trial with Cetuximab and Irinotecan (CetIri) for patients with platinum resistant esofagus- or gastric cancer - CetIri |
| Scientific title | Phase II trial with Cetuximab and Irinotecan (CetIri) for patients with platinum resistant esofagus- or gastric cancer - CetIri |
| Primary sponsor | Odense University Hospital |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Denmark |
| Conditions | Patients with esofagus- and gastric cancer MedDRA version: 9.1 Level: LLT Classification code 10017758 Term: Gastric cancer |
| Interventions | Trade Name: Erbitux 5 mg/ml Pharmaceutical Form: Solution for infusion INN or Proposed INN: Cetuximab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- Trade Name: CAMPTO Product Name… |
| Registration date | Oct 21, 2008 |
| Target size | 55 |
| Secondary IDs | 08.14 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: